IMPACT Publications

Publications

Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJUI (Sept, 2010, 14, doi: 10.1111/j.1464-410X.2010.09648.x.

Mitra AV, Jameson C, Barbachano Y, et al. Elevated expression of Ki-67 identifies aggressive prostate cancer but does not distinguish BRCA1 and BRCA2 mutation carriers. Oncol Rep. 2010;23(2):299-305.

Mitra A, Jameson C, Y. Barbachano, N. Sodha, Z. Kote-Jarai, A. Javed, E. Bancroft, A. Fletcher, Christopher S. Foster, C. Cooper, S. Peock, D. Easton, R. Eeles. Overexpression of TP53 is Associated with Aggressive Prostate Cancer but does not Distinguish Disease in BRCA1 or BRCA2 Mutation Carriers from a Control Group. The Open Prostate Cancer Journal 2009;2:38-45

Whitaker H, Kote-Jarai Z, Ross-Adams H, Warren A, Burge A, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman G, Evans DG, Blanco I, Mercer S, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Lilja H, Easton D, The IMPACT Study Steering Committee, The IMPACT Study Collaborators, Cooper C, Eeles R, Neal, D. The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. PLoS ONE 5(10): e13363. doi:10.1371/journal.pone.0013363

 Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S , Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D on behalf of The IMPACT Steering committee and IMPACT and EMBRACE Collaborators, *Eeles R, *Foster CS (joint last authors). Over-expression of RAD51 occurs in aggressive prostate cancer. Histopathology, in press.

Mitra A, Fisher C, Foster CS, Jameson C, Barbachano Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D, Eeles R (2008) Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. British J Cancer 98: 502-7

Morgan S, Doherty R , Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, Bancroft, E, Mitra A, Morgan S Eeles R (2006). AIDIT and IMPACT: Strengthening Research Ties Across Eastern Europe. HCCP 4(2): 111-112

Doherty R, Lubinsi J, Manguoglu E, Luleci G, Christie M, Craven P, Bancroft E, Mitra A, Morgan S, Eeles R AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening (2006). J BUON. Oct-Dec; 11(4):415-8.

Mercer C, Eccles D, Mitra A, Bancroft E, Eeles R. The Genetics of Prostate Cancer and the Potential for Targeted Screening: the IMPACT study (2007). Oncology News, Volume 2 Issue 2, August/September.

Mitra AV, Bancroft EK, Eeles RA et al, A Review of Targeted Screening For Prostate Cancer. Introducing the IMPACT Study (2007) BJU Int. Jun;99(6):1350-5.

Abstracts

Mitra A, Bancroft E, Eeles R et al Targeted Screening in Men with a Genetic Predisposition to Prostate Cancer. The IMPACT Study. Clin Oncol (R Coll Radiol). (2007) Apr;19(3 Suppl):Abstract S39-40

Mitra AV, Bancroft EK, Eeles RA Identification of men with a genetic predisposition to prostate cancer: Targeted screening in BRCA1/2 mutation carriers and controls. The IMPACT study (2007). American Society Clinical Oncology (ASCO) Prostate Cancer Symposium Feb Abstract No.42

Mitra A, Bancroft E, Eeles R et al. Targeted Screening in Men with a Genetic Predisposition to Prostate Cancer The IMPACT Study (2006). British Prostate Group, Autumn meeting

Mitra A, Bancroft E, Eeles R. Identification of Men with a Genetic Predisposition to Prostate Cancer – Targeted Screening in BRCA1/2 Mutation Carriers and Controls: the IMPACT Study. (2006) 11th International Congress of Human Genetics, Brisbane Australia.

Home